Search Results
Results found for "Helen Su"
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
But that model is no longer sufficient. Subscribers gain access to: Weekly lessons by Dr.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
assays Why Intracellular GPCR Drugs Change the Game For decades, drug design has treated GPCRs as surface And while that strategy has yielded enormous success, it ignores a powerful reality: the cytosol is a He also reviews key scaffold properties that determine success, offering practical tips for design teams GPCRs Aren’t Just Surface Receptors Anymore From β2-adrenoreceptors to CCRs and dopamine receptors, multiple Subscribe to The Kenakin Brief today ➤ #GPCRs #IntracellularDrugs #DiffusionBarriers #DrugResidenceTime
- How Fast Does a Drug Work?
Kenakin’s latest lecture delivers exclusive, real-world insight designed to equip you to move beyond surface-level framework for understanding when a drug’s rate of binding onset and offset matter most for in vivo success well-informed decisions that move promising candidates forward while de-prioritizing those unlikely to succeed Your Pipeline Many workflows still operate on the assumption that equilibrium potency (Kd) alone is sufficient Missteps at this level can delay optimization, generate unnecessary SAR work, or cause your team to miss subtle
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
. 🔍 Quick Wins This Week 🔹 Tell us what matters → News Survey Your 1-minute feedback shapes what GPCR Podcast - Surviving Discovery’s Gauntlet Dr. Sokhom Pin delivers brutally honest insights.
- Your GPCR Program Decisions Depend on Good Data Interpretation
Subtle misinterpretation can quietly derail projects, slow timelines, and waste scarce resources. startup environments Read Maria Majellaro's Full Recap ➤ Lab Leadership Without Ego: A Model for R&D Success pharmacology group from scratch—not just a lab, but a culture that encouraged curiosity, empowered people, and supported for attitude and team fit—not just credentials Design workflows that enable curiosity-driven research Support
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
This Week in Premium: Sneak Peek Industry insights: Strategic biotech alliances (Chemspace/Enamine, Superluminal As the GPCR field surges forward—from ligand bias to signaling diversity—the guest editors Dr. Your work belongs in the core conversation—not buried in supplementary files. Volume II isn’t about repetition—it’s about redefining signal transduction. 📝 Manuscript summary deadline : 23 Sept 2025 📄 Submission deadline: 11 Jan 2026 Submit to Volume II ➤ Discovery On Target: Where the
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Power of Intracellular GPCR Drugs For years, GPCR drug discovery has focused on targets at the cell surface in vivo disconnect: Understand why traditional potency measurements often fail to predict clinical success your computational toolkit ➤ Call for Papers: GPCRs: Signal Transduction, Volume II Building on the success Also super-valuable for those of us learning how to teach pharmacology” — Dr. To succeed, you need to move beyond standard approaches and adopt the frameworks that are driving real
- From Venice to Virtual Molecules: Alessandro Nicoli’s Unexpected Journey into Computational Chemistry
Suddenly, chemistry wasn’t just synthetic—it was strategic. With hundreds of subtypes and limited ligand data, olfactory GPCRs represent a high-risk, high-reward
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
These findings suggest a path forward that isn’t about blocking a single receptor but about rewiring weaker than if you were hitting a GPCR... and honestly, like with the trials, they were not really that sufficiently And in itself, that's kind of a suggestion.” Serafini’s work on RGS proteins suggests a quieter, but no less powerful, frontier in the fight against
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
designed to keep you ahead without noise or delays: Industry insights: Structure-Based Drug Design Summit Rethink translational success: How post-COVID insights and unconventional decision-making shaped Serafini
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientist’s Mission
After years of living with unresolved pain following surgery for a pilonidal cyst, Alex was left without
- Understanding Orthosteric Binding: The Key to Drug Action
Implications for Drug Development As drug developers, understanding these nuances can significantly impact the success
- Accelerating GPCR Drug Discovery
Systems That Drive Progress: From assay tracking to data workflows, I design simple, scalable tools that surface
- From GPCR Data Chaos to Decisive Action
Not possible when nothing’s built to surface the right insights early. I install simple tools that surface insights, align your team, and keep momentum moving. My Consulting Philosophy Every successful GPCR program is a blend of scientific excellence and operational need clarity ✅ Yamina’s Corner helps teams move from data chaos to decisive action ✅ This is hands-on support
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
receptor antagonists at BMS to opioid receptor research at Alkermes and early-stage work at Cerevel and Superluminal
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
team fit , not just credentials He designed lab workflows that encouraged curiosity without burnout He supported Sokhom knew this instinctively and built a system to support it.
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
Watch Episode 169 What if you could earn a PhD while supporting a family and working full time in drug
- Pharmacology at Your Fingertips: Terry’s Corner Launches
Plus: must-read chemokine and PTH1R papers, and new momentum across biotech—from Superluminal to Neurocrine Terry Kenakin with short videos, clear summaries, and curated references. execution, and scalable systems, it turns scattered data into decisions, accelerating your path to a successful
- What If the Most Important Part of Your Drug Isn’t What It Binds—But What It Does?
You'll learn why some agonists succeed in sensitive tissues but fail elsewhere—and how this knowledge
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
Here’s the surprising truth: up to 80% of GPCR-targeted drugs fail—not because of poor chemistry, but
- Beyond the Probe: Scaling Innovation From the Bench to Product Launch
Whether supporting CROs, academic labs, or pharma teams, Celtarys engages deeply with collaborators to chemical probes and make assay development faster, cheaper, and more customizable. 👉 See how Celtarys can support
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
Subscribe to The Kenakin Brief below to stay in the know. development contexts Advance with nuanced lessons on allostery, residence time, and translational PK/PD Subscribe CXCR4 oligomerization sustains oncogenic signaling in lymphoid neoplasms, and its disruption boosts
- The Chemistry of Confidence: Aha Moments That Shape Scientific Careers
Watch Episode 168 Success in science is rarely linear. In fact, her early decisions were based on curiosity, instinct, and a surprising love of cooking (yes
- From Multiplex to Models: Scaling Up GPCR Discovery in the Post-Silo Era
Kotliar sums it up best: “We went from one receptor to many… and now, from many, we can go back to one
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
Watch Episode 167 What started with a single receptor became a toolset for an entire superfamily.
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
Knowing the difference is survival.
- Science Needs Rigor, But Also Joy
• Leadership that supports academic career paths • A team that communicates under pressure • Space
- New Podcast, Sweet Structures & $2.2B GPCR Moves
Show off your receptor pride and support the mission. The official Dr. GPCR Store is live! A stunning cryo-EM structure of the sweet taste receptor (TAS1R2–TAS1R3) shows how aspartame and sucralose From sugar-sensing structures to strategic partnerships—GPCRs remain at the center of it all.
- Inverse Agonists, Lymphatic Fixes & β-arrestin Tricks
Every insight you share helps us build a smarter, more supportive GPCR community—together. It’s a simple way to share valuable resources and support the field—one connection at a time.
